Additionally, the predicted features included other key factors, such as age, ECOG performance status, and cytogenetic abnormalities, as well as FLT3-ITD, CEBPA, and NPM1 mutations, as primary drivers of AML progression. Here, NPM1 is linked to acute myeloid leukemia.